226998-04-5

Basic information

• Product Name: 4-Thiazolidinecarboxamide, 5,5-dimethyl-N-[(2-methylphenyl)methyl]-, (4R)-
• CAS NO: 226998-04-5
• Molecular Formula: C14H20N2OS
• Molecular Weight: 264.392
• Mol File: 226998-04-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-Thiazolidinecarboxamide, 5,5-dimethyl-N-[(2-methylphenyl)methyl]-, (4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolidinecarboxamide, 5,5-dimethyl-N-[(2-methylphenyl)methyl]-, (4R)-(226998-04-5)
• EPA Substance Registry System: 4-Thiazolidinecarboxamide, 5,5-dimethyl-N-[(2-methylphenyl)methyl]-, (4R)-(226998-04-5)

Safety Data

• Hazardous Substances Data: 226998-04-5(Hazardous Substances Data)

Upstream product

• 1113-41-3 L-penicillamine 
• 14865-38-4 o-tolylmethanamine monohydrochloride 
• 2524-64-3 chlorophosphoric acid diphenyl ester 
• 117918-23-7 (R)-3-tert-butoxycarbonyl-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 89-93-0 ortho-methylbenzylamine 
• 1499-21-4 Diphenylphosphinic chloride 
• 72778-00-8 (R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 321434-78-0 5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidine-3-carboxylic acid tert-butyl ester 

Downstream Products

• 186538-00-1 (R)-N-(2-methylbenzyl)-3-[(2S,3S)-2-hydroxy-3-[3-hydroxy-2-methylbenzoyl]amino-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 
• 1054648-28-0 acetic acid 3-{(1S,2S)-1-benzyl-3-[(4R)-5,5-dimethyl-4-(2-methyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 1070147-91-9 C₃₉H₄₁N₃O₅S 
• 1217206-70-6 C₃₂H₄₃N₃O₅S 
• 1217206-73-9 C₂₉H₄₁N₃O₄S 
• 186538-15-8 (R)-N-(2-methylbenzyl)-3-[(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 

Relevant articles and documents

Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors

The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-I). We recently unveiled a potent hexapeptidic HTLV-I protease inhibitor, KNI-10166, compose

Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure

A series of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing substituted allophenylnorstatine [Apns: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] were designed and synthesized. From the structure-metabolism relationship of this type of HIV protease inhibitors, the compounds having para substitution of the phenyl ring of Apns and/or 2,6-disubstitution of the P2′ benzylamine were found to be able to avoid the P2 phenol glucuronidation that occurs with SM-319777 (formerly named JE-2147, KNI-764); one of the main metabolic pathways of SM-319777. These new analogues, such as SM-322377, had more desirable pharmacokinetic profiles and more potent antiviral activity against not only wild type HIV-1 but also the multi-drug-resistant HIV-1 than SM-319777.

Tripeptide compounds and anti-AIDS medicine

A novel tripeptide compound represented by the following general formula (I) exhibiting superior HIV protease inhibition activity, and an anti-AIDS medicine comprising this compound as an effective component and a pharmaceutically acceptable salt thereof.